Prognostic Markers in Bladder Cancer
Author Information
Author(s): Yuk Hyeong Dong, Han Jang Hee, Jeong Seung-Hwan, Jeong Chang Wook, Kwak Cheol, Ku Ja Hyeon
Primary Institution: Seoul National University Hospital
Hypothesis
The study evaluates the prognostic potential of specific tumor markers in bladder cancer.
Conclusion
Elevated serum levels of β-hCG and CA125 are associated with poorer overall and recurrence-free survival in bladder cancer patients.
Supporting Evidence
- The proportion of abnormal β-hCG, CA19-9, and CA125 was significantly higher in locally advanced bladder cancer than in organ-confined bladder cancer.
- Patients with preoperative β-hCG and CA125 abnormalities had poor prognosis for recurrence-free survival and overall survival.
- Both β-hCG and CA125 were found to be significant independent factors for predicting overall survival and recurrence-free survival.
Takeaway
Doctors looked at blood tests to see if certain markers could help predict how bladder cancer patients would do after surgery. They found that higher levels of some markers meant worse outcomes.
Methodology
The study analyzed records of 369 patients who underwent radical cystectomy for urothelial cancer, measuring levels of specific tumor markers before surgery.
Potential Biases
Selection bias may exist due to the retrospective nature of the study.
Limitations
The study is retrospective, has a small cohort size for certain subgroups, and is based on data from a single institution.
Participant Demographics
The median age of participants was 69 years, with 77.2% being male.
Statistical Information
P-Value
P<0.001 for β-hCG and CA125 abnormalities related to survival outcomes.
Confidence Interval
95% CI: 1.43–10.25 for β-hCG; 95% CI: 1.34–32.16 for CA125.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website